The SELECT trial proved that GLP-1 agonism alone reduces major cardiovascular events by 20% in at-risk patients
doi: World (2021)
Moving forward, a collaborative, multicenter, research-driven approach will be crucial to unlock the therapeutic potential of these agents, potentially revolutionizing PTC treatment
Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance
"Fatigue related to tirzepatide is usually temporary and improves as the body adjusts to the medication," notes Eapen, MD
And, you know, that's a good and a bad thing, I guess, but at the end of the day, we still want patients to be evaluated properly, so that we know the right people are getting the right drug